POLBF (Poolbeg Pharma) Receivables Turnover : 0.00 (As of Jun. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Poolbeg Pharma Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Poolbeg Pharma's Revenue for the six months ended in Jun. 2024 was $0.00 Mil. Poolbeg Pharma's average Accounts Receivable for the six months ended in Jun. 2024 was $0.01 Mil.

Poolbeg Pharma Receivables Turnover Historical Data

The historical data trend for Poolbeg Pharma's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Poolbeg Pharma Receivables Turnover Chart

Poolbeg Pharma Annual Data

Trend

Dec21

Dec22

Dec23

Receivables Turnover

Poolbeg Pharma Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Receivables Turnover	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Poolbeg Pharma's Receivables Turnover

For the Biotechnology subindustry, Poolbeg Pharma's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Poolbeg Pharma's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Poolbeg Pharma's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Poolbeg Pharma's Receivables Turnover falls into.

Save Embed

;

Save Embed

;

Poolbeg Pharma Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Poolbeg Pharma's Receivables Turnover for the fiscal year that ended in Dec. 2023 is calculated as

	Receivables Turnover (A: Dec. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Dec. 2023 )	/ (	(Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )
=	0	/ (	(0	+	0)	/	1 )
=	0	/	0
=	N/A

Poolbeg Pharma's Receivables Turnover for the quarter that ended in Jun. 2024 is calculated as

	Receivables Turnover (Q: Jun. 2024 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Jun. 2024 )	/ (	(Accounts Receivable (Q: Dec. 2023 )	+	Accounts Receivable (Q: Jun. 2024 ))	/	count )
=	0	/ (	(0	+	0.014)	/	1 )
=	0	/	0.014
=	N/A

Poolbeg Pharma (OTCPK:POLBF) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Poolbeg Pharma Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Poolbeg Pharma's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Poolbeg Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Poolbeg Pharma PLC (OTCPK:POLBF) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

POLB:UK 7JN:Germany

Address

42 New Road, Queen Mary BioEnterprises Innovation Centre, London, GBR, E1 2AX

Website

https://www.poolbegpharma.com

Poolbeg Pharma PLC is a clinical-stage infectious disease pharmaceutical company, with a novel capital-light clinical model which enables to develop of multiple products faster and more cost-effectively than the traditional biotech model. The company aspires to become a one-stop shop for pharma-seeking mid-stage products to license or acquire.